Screener
ARS Pharmaceuticals, Inc. SPRY Pre-Tax Income
Pre-Tax Income at other companies
Other financials
Where this comes from
Reported directly by ARS Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest.
The source filing: ARS Pharmaceuticals, Inc.’s 10-K, filed March 9, 2026.
- Filed
- Mar 9, 2026, 6:07 AM EDT
- Fiscal year
- FY2025
- Accession
- 0001193125-26-097478
| Line item | Years Ended December 31, 2025 | Years Ended December 31, 2024 |
|---|---|---|
| Interest income | 10,669 | 11,369 |
| Interest expense (including related party amounts of $130 and $0, respectively) | (2,599) | — |
| Total other income, net | 8,070 | 11,369 |
| (Loss) income before income tax (benefit) expense | (171,378) | 8,286 |
| Income tax (benefit) expense | (80) | 288 |
| Net (loss) income | (171,298) | 7,998 |
| Unrealized (losses) gains on available-for-sale securities | (95) | 171 |
| Comprehensive (loss) income | $(171,393) | $8,169 |
Item 8. Financial Statements and Supplementary Data
FAQ
- What is ARS Pharmaceuticals, Inc.'s pre-tax income?
- ARS Pharmaceuticals, Inc. (SPRY) reported pre-tax income of -$42.84M in Q4 2025.
- How has ARS Pharmaceuticals, Inc.'s pre-tax income changed year-over-year?
- ARS Pharmaceuticals, Inc.'s pre-tax income decreased by 2168.3% year-over-year, from $2.07M to -$42.84M.
- What is the long-term trend for ARS Pharmaceuticals, Inc.'s pre-tax income?
- Over 2 years (2023 to 2025), ARS Pharmaceuticals, Inc.'s pre-tax income has grown at a 77.5% compound annual growth rate (CAGR), from -$54.37M to -$171.38M.
- What does pre-tax income mean?
- Total income from all sources — operating income plus non-operating items like interest income, investment gains, and other income — before the provision for income taxes.
Ask your AI about ARS Pharmaceuticals, Inc.'s pre-tax income.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude